LEO Pharma announced that it's new drug, Xamiol, for treatment of scalp psoriasis – has been approved in 16 European countries.

The UK will be the first country to market Xamiol. This is scheduled to take place in the fourth quarter this year. In extensive clinical studies Xamiol has proved to be a very efficient drug in the treatment of the chronic skin disease psoriasis, when it occurs in the patient's scalp. Moreover, preliminary market surveys indicate that patients, doctors and dermatologists have great expectations to Xamiol.

Gitte P Aabo, CEO in LEO Pharma said, "The approval of Xamiol opens up for amazing opportunities for LEO Pharma and the tens of thousands of psoriasis patients that have requested an efficient drug for treatment of the serious and visible scalp psoriasis. With the upcoming launch of Xamiol in Europe, LEO has taken a significant step towards realizing our objective to offer patients the best and most complete treatment of their psoriasis."

He added, "With Xamiol the patients get a long sought-after drug that will result in an improving difference in their quality of life, when it comes to the uncomfortable scalp psoriasis."

Psoriasis is a disorder which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Plaques frequently occur on the skin of the elbows and knees, but can affect any area including the scalp and genitals.

Scalp psoriasis is very common. In fact, at least half of all people who have psoriasis have it on their scalp. As with psoriasis elsewhere on the body, skin cells grow too quickly on the scalp and cause red lesions covered with scale to appear.

Other skin disorders, such as seborrheic dermatitis, may look similar to psoriasis, but there are differences. Scalp psoriasis scales appear powdery with a silvery sheen, while seborrheic dermatitis scales often appear yellowish and greasy. Despite these differences, the two conditions can be easily confused.

LEO Pharma is an independent research based company with headquarters in Ballerup, Denmark. LEO Pharma is wholly-owned by the LEO Foundation and is a globally leading company within Dermatology and Critical Care.